Skip to content

The RASCAL study (refractory angina spinal cord stimulation and usual care)

A multicentre randomised controlled trial of Spinal Cord Stimulation plus usual care vs. usual care alone in the management of Refractory Angina: a feasibility & pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65254102
Enrollment
45
Registered
2011-04-12
Start date
2011-05-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory angina Circulatory System Angina pectoris

Interventions

Participants will be randomised to receive either a spinal cord stimulator (SCS) with usual care or to receive usual care alone. One group will therefore have a SCS implanted following a successful

Sponsors

South Tees Hospitals NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Limiting angina despite optimal anti-angina therapy 2. Canadian Cardiovascular Society Functional Classification of Angina (CCS) Class III and IV 3. Angiographically documented coronary artery disease (CAD) 4. CAD not suitable for revascularisation in the opinion of the referring cardiologist/cardiothoracic surgeon 5. Satisfactory multidisciplinary assessment in accordance with British Pain Society (BPS) guidelines for SCS 6. Demonstrable ischaemia on functional testing

Exclusion criteria

Exclusion criteria: 1. Presence of pacemaker or implanted defibrillator that is incompatible with SCS 2. Patient refusal to participate in the study 3. Presence of co morbidity considered by the assessing clinician to overshadow the effect of the angina or render them an unsuitable candidate for neuromodulation (e.g. advanced spinal disease or deformity) 4. Poor cognitive ability 5. Ongoing anticoagulation therapy, where anticoagulants cannot be safely discontinued without jeopardising patient safety

Design outcomes

Primary

MeasureTime frame
HRQoL as measured using the disease-specific measure the Seattle angina questionnaire (SAQ) UK version. We expect the SAQ to be the primary outcome in the definitive trial.

Secondary

MeasureTime frame
1. Intake of angina medications and angina attacks 2. Exercise capacity (at baseline and 6-months only) 3. Complications and adverse events 4. Healthcare utilisation (e.g. cardiac specific hospitalisations and primary care visits, management of complications/adverse events) 5. Generic measures HRQoL will be assessed using the EuroQol (EQ-5D) and Short Form -36 (SF-36) questionnaires

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 24, 2026